1527-3350/asset/cover.gif?v=1&s=3cd983af6575c8dbfd6b47a63ffa95415ace15f8 "Hepatology")
fax: (32) 2-555-46-97
1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
Viral Hepatitis
You have full text access to this OnlineOpen article
CCR5 deficiency exacerbates T-cell–mediated hepatitis in mice†
Article first published online: 20 SEP 2005
DOI: 10.1002/hep.20865
Copyright © 2005 American Association for the Study of Liver Diseases
Additional Information
How to Cite
Moreno, C., Gustot, T., Nicaise, C., Quertinmont, E., Nagy, N., Parmentier, M., Le Moine, O., Devière, J. and Louis, H. (2005), CCR5 deficiency exacerbates T-cell–mediated hepatitis in mice. Hepatology, 42: 854–862. doi: 10.1002/hep.20865
- †
Potential conflict of interest: Nothing to report.
Publication History
- Issue published online: 20 SEP 2005
- Article first published online: 20 SEP 2005
- Manuscript Accepted: 18 JUL 2005
- Manuscript Received: 7 FEB 2005
Funded by
- Fondation Erasme
- Fonds National de la Recherche Scientifique of Belgium
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , , , , CCR5 Deficiency Does Not Reduce Hypertensive End-Organ Damage in Mice, American Journal of Hypertension, 2012, 25, 4, 479
- 2, , , Drug safety evaluation of maraviroc for the treatment of HIV infection, Expert Opinion on Drug Safety, 2012, 11, 1, 161
- 3, , , Multiple Factors Govern the Association between Pharmacology and Toxicity in a Class of Drugs: Toward a Unification of Class Effect Terminology, Chemical Research in Toxicology, 2011, 24, 4, 463
- 4, , , Therapeutic potential of chemokine receptor antagonists for liver disease, Expert Review of Clinical Pharmacology, 2011, 4, 4, 503
- 5, , , Functional role of chemokines in liver disease models, Nature Reviews Gastroenterology & Hepatology, 2010, 7, 12, 682
- 6, , , , , , , , , , Hepatic safety and tolerability in the maraviroc clinical development program, AIDS, 2010, 24, 17, 2743
- 7, , The role of chemokines in the recruitment of lymphocytes to the liver, Journal of Autoimmunity, 2010, 34, 1, 45
- 8, , , , , , , , , CCR1 and CCR5 promote hepatic fibrosis in mice, Journal of Clinical Investigation, 2009,
- 9, , , , , , , CCR5 is involved in resolution of inflammation in proteoglycan-induced arthritis, Arthritis & Rheumatism, 2009, 60, 10Direct Link:
- 10, , , , , , , , , , Dual Role of CCR2 in the Constitution and the Resolution of Liver Fibrosis in Mice, The American Journal of Pathology, 2009, 174, 5, 1766
- 11, , , , , , , Hepatocyte Transplantation-Induced Liver Inflammation Is Driven by Cytokines-Chemokines Associated With Neutrophils and Kupffer Cells, Gastroenterology, 2009, 136, 5, 1806
- 12, Safety concerns about CCR5 as an antiviral target, Current Opinion in HIV and AIDS, 2009, 4, 2, 131
- 13, A New Class of Anti-HIV Therapy and New Challenges, New England Journal of Medicine, 2008, 359, 14, 1509
- 14, , , , Chemokine-directed immune cell infiltration in acute and chronic liver disease, Expert Review of Gastroenterology & Hepatology, 2008, 2, 2, 233
- 15, , , , , , , , , , , , , , , , , , , , , Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection, New England Journal of Medicine, 2008, 359, 14, 1442
- 16, , , , , , Tetrandrine protects mice from concanavalin A-induced hepatitis through inhibiting NF-κB activation, Immunology Letters, 2008, 121, 2, 127
- 17
- 18, , , Access denied? The status of co-receptor inhibition to counter HIV entry, Expert Opinion on Pharmacotherapy, 2007, 8, 7, 923
- 19, , , , , , , Amyloid fibrils formation and amorphous aggregation in concanavalin A, Biophysical Chemistry, 2007, 125, 1, 184
- 20, Antiretroviral therapy-induced liver alterations, Current Opinion in HIV and AIDS, 2007, 2, 4, 293
- 21, Autoimmune hepatitis. Part A: pathogenesis, Expert Review of Gastroenterology & Hepatology, 2007, 1, 1, 113
- 22, , , , , , CCR5 Deficiency Drives Enhanced Natural Killer Cell Trafficking to and Activation within the Liver in Murine T Cell-Mediated Hepatitis, The American Journal of Pathology, 2007, 170, 6, 1975
- 23, , Chemokine Antagonists as Therapeutics: Focus on HIV-1, Annual Review of Medicine, 2007, 58, 1, 445
- 24, , , , Effects of succinylation on thermal induced amyloid formation in Concanavalin A, European Biophysics Journal, 2007, 36, 7, 733
- 25, , , Pathogenesis of autoimmune hepatitis: from break of tolerance to immune-mediated hepatocyte apoptosis, Translational Research, 2007, 149, 3, 107
- 26, , , , , , , , , , , , , A DNA vaccine encoding CCL4/MIP-1β enhances myocarditis in experimental Trypanosoma cruzi infection in rats, Microbes and Infection, 2006, 8, 12-13, 2745
- 27, , , , , , , , , , , , , Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea, Journal of Medical Virology, 2006, 78, 12Direct Link:
- 28, , Can gene delivery close the door to HIV-1 entry after escape?, Journal of Medical Primatology, 2006, 35, 4-5Direct Link:
- 29, , , CCR5 antagonists: the answer to inflammatory disease?, Expert Opinion on Therapeutic Patents, 2006, 16, 8, 1051
- 30, , CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice — Clinical implications for CCR5 inhibition as antiretroviral therapy, Hepatology, 2006, 43, 4Direct Link:
- 31, Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients, The Lancet, 2006, 367, 9512, 711
- 32
- 33, Lack of chemokine receptor CCR5 promotes murine fulminant liver failure, Hepatology, 2006, 44, 1Direct Link:
- 34